Skip to main content

Year: 2024

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to accelerate overall development timelines; completion of both expanded trials expected by mid-2026 KT-295, a new TYK2 degrader, selected as the development candidate to advance into Phase 1 clinical trial in the first half of 2025, in line with prior program guidance Company to shift focus and resources from oncology to its expanding immunology pipeline, and will only advance KT-333 (STAT3) and KT-253 (MDM2) beyond Phase 1 with a partner Well-capitalized with $911 million in cash as of September 30, 2024, and runway into mid-2027 Company to hold call and webcast today at 8:30 a.m. ET WATERTOWN,...

Continue reading

Repligen to Report Third Quarter 2024 Financial Results

Webcast and Conference Call to Be Held Tuesday, November 12, 2024, at 8:30 a.m. ET WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2024. Olivier Loeillot, President and Chief Executive Officer of Repligen said, “Our team continues to work diligently to complete the required revenue restatements as disclosed on September 18. We plan to file the amended periodic reports related to the required revenue restatements and to announce our third quarter of 2024...

Continue reading

Red Pine Discovers Significant Gold Mineralization in Faulted Extension of the Jubilee Shear on the Wawa Gold Project

TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) — Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) (“Red Pine” or the “Company”) is pleased to announce the assay results from an additional 13 drill holes representing 2,725 metres (“m”) of assayed core length as part of the completed 2022-2024 drilling program at the Wawa Gold Project, Ontario. As part of its property-wide surface prospecting program initiated in July 2024, Red Pine revisited various holes drilled between 2022 and 2024. In one of the relogged drill holes designed to test the faulted offset of the Jubilee Shear, significant gold mineralization was discovered. This gold mineralization has geological attributes comparable to the zones of mineralization in the Jubilee Shear which form the current 2024 Mineral Resource Estimate (“MRE”) described in National Instrument 43-101...

Continue reading

Stardust Power Engages MUFG as Lead Financial Advisor for Its Battery-Grade Lithium Refinery in Oklahoma

GREENWICH, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) — Stardust Power Inc. (NASDAQ: SDST) (“Stardust Power” or the “Company”), an American developer of battery-grade lithium products, announced that it has engaged MUFG Bank, Ltd. (“MUFG”) as lead financial advisor in relation to the Company’s development of one of the largest battery-grade lithium refining facilities in the United States. MUFG has been engaged to play a crucial role in supporting fundraising and advisory services in connection with the development of the first phase of Stardust Power’s Muskogee, Oklahoma project. The Company expects that the initial facility build-out will focus on establishing a phase one capacity of 25,000 metric tons per annum of battery-grade lithium carbonate. The completion of the first phase of the project will establish Stardust Power as one...

Continue reading

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs

PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence Biomedical has issued common shares to Psyence Group pursuant to a debt-for-equity swap agreement NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the successful closing of its previously announced acquisition of Psyence Group’s 11.13% stake in privately held PsyLabs.    PsyLabs is focused on the cultivation and production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical trials and drug development. As previously announced, Psyence Biomed and PsyLabs have an existing strategic partnership whereby PsyLabs has granted Psyence Biomed a worldwide, exclusive,...

Continue reading

HII Reports Third Quarter 2024 Results and Provides Updated Outlook

NEWPORT NEWS, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) — HII (NYSE: HII) today reported results for the third quarter of fiscal 2024 and provided an update on its outlook. HighlightsThird quarter revenues were $2.7 billion Third quarter net earnings were $101 million or $2.56 diluted earnings per share Third quarter free cash flow1 was $136 million Company is providing updated fiscal 2024 outlook Company is withdrawing 5-year free cash flow1 outlookThird Quarter Results Third quarter 2024 revenues of $2.7 billion were down 2.4% from the third quarter of 2023, driven by lower volume at Ingalls Shipbuilding and Newport News Shipbuilding, partially offset by growth at Mission Technologies. Operating income in the third quarter of 2024 was $82 million and operating margin was 3.0%, compared to $172 million and 6.1%, respectively, in...

Continue reading

Anika Reports Third Quarter 2024 Financial Results

Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds Strategy to focus on market leading OA Pain Management and high-growth Regenerative Solutions Company to categorize revenue into OEM Channel and Commercial Channel; Commercial Channel remains on track to achieve ~17% CAGR since 2021 with recent performance fueled by the IntegrityTM Implant System, which grew 40%+ sequentially in the third quarter with more than 500 surgeries since launch First module of Hyalofast® PMA filed in October; important hurdle addressed regarding Cingal® NDA filing path BEDFORD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early...

Continue reading

Kimco Realty® Announces Third Quarter 2024 Results

– Portfolio Occupancy Matches All-Time High – – Board Increases Quarterly Cash Dividend on Common Shares by 4.2% – – Raises 2024 Outlook – JERICHO, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) — Kimco Realty® (NYSE: KIM), a real estate investment trust (REIT) and leading owner and operator of high-quality, open-air, grocery-anchored shopping centers and mixed-use properties in the United States, today reported results for the third quarter ended September 30, 2024. For the three months ended September 30, 2024 and 2023, Kimco Realty’s net income available to the company’s common shareholders per diluted share was $0.19 and $0.18, respectively. Third Quarter HighlightsGrew Funds From Operations* (“FFO”) 7.5% over the same period in 2023 to $0.43 per diluted share. Produced 3.3% growth in Same Property Net Operating Income* (“NOI”) over...

Continue reading

Gildan Reports Record Third Quarter Revenue and Adjusted Diluted EPS¹ and Updates its Full Year 2024 Guidance

 (all amounts are in U.S. dollars except where otherwise indicated)(1) Please refer to “Definition and reconciliation of non-GAAP financial measures” in this press release Record third quarter net sales of $891 million, up 2.4% vs. the prior year Operating margin of 21.7%, adjusted operating margin1 of 22.4% GAAP diluted EPS of $0.82 and record third quarter adjusted diluted EPS1 of $0.85 Cash flow from operations of $178 million and free cash flow1 of $149 million Record quarterly return of $404 million to shareholders through dividends and share repurchases Company updates its full year 2024 guidanceMONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) — Gildan Activewear Inc. (GIL: TSX and NYSE) today announced results for the third quarter ended September 29, 2024. The Company also updated its Fiscal 2024...

Continue reading

JD.com to Report Third Quarter 2024 Financial Results on November 14, 2024

BEIJING, Oct. 31, 2024 (GLOBE NEWSWIRE) — JD.com, Inc. (NASDAQ: JD and HKEX: 9618 (HKD counter) and 89618 (RMB counter), a leading supply chain-based technology and service provider, today announced that it plans to release its unaudited third quarter 2024 financial results on Thursday, November 14, 2024, before the U.S. market opens. JD.com’s management will hold a conference call at 7:00 am, Eastern Time on November 14, 2024, (8:00 pm, Beijing/Hong Kong Time on November 14, 2024) to discuss the third quarter 2024 financial results. Please register in advance of the conference using the link provided below and dial in 15 minutes prior to the call, using participant dial-in numbers, the Passcode and unique access PIN which would be provided upon registering. You will be automatically linked to the live call after completion of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.